Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
This study is to determine if an oral drug called Ramipril can lower the chance of memory
loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during
chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using
several neurocognitive tests throughout the duration of the study.
Intervention
Ramipril
Condition
Glioblastoma, Radiotherapy; Complications, Cognitive Decline, Chemoradiation
Investigators
Michael D Chan, MD, Daniel H. Barnett, Aaron G. Mammoser, Anand Mahadevan, Volker W. Stieber, Pamala A. Pawloski, Timothy D. Moore, Bryan A. Faller, Collin D. Driscoll, Richard M. Green, Robert J. Behrens, Preston D. Steen, Bret E. Friday, Scott M. Lindhorst, Benjamin E. Lawler, Vinay K. Gudena, Kathleen J. Yost, Gena H. Volas-Redd, Richard L. Deming, Benny J. Liem, Howard A. Zaren, Glenn J. Lesser, Robert J. Isaak, Jay W. Carlson, James E. Radford, Alison K Conlin, Richard L Deming, Jay W Carlson, Daniel H Barnetter, Timothy D Moore, Gregory A Masters, Samir Narayan, Stuart Y Tsuji, Daniel H Barnett, Bryan A Faller, Thomas E Lad, Joshua Lukenbill, Seth J Page, Gary V Burton, Kathleen J Yost, Bret EB Friday, Preston D Steen, Pamala A Pawloski, Pamela A Pawloski, Vinay K Gudena, Glenn J Lesser, Volker W Stieber, Benny J Liem, Ki Y Chung, Howard A Zaren, Harish G Ahuja, Asadullah Khan